Oral weight-loss tablets set to enter German pharmacies this autumn, expanding access beyond injectable GLP-1 drugs
Executive summary: German pharmacies will begin selling oral weight-loss tablets starting this autumn, expanding access beyond existing injectable options. The introduction of pills could increase patient adherence and broaden the anti-obesity drug market by offering a more convenient alternative to injections.
Who is involved: German pharmacies, pharmaceutical manufacturers of oral GLP-1 or similar weight-loss agents, and patients seeking obesity treatment.
Likely next: Regulatory clarity on pricing and reimbursement, potential uptake by patients, and monitoring of real-world effectiveness and safety in outpatient settings.
German pharmacies will begin offering oral weight-loss tablets starting this autumn, marking a shift from the current dominance of injectable GLP-1 receptor agonists like semaglutide. The move aims to improve patient convenience and adherence, potentially broadening the market for anti-obesity medications. However, details on pricing, reimbursement, and specific active ingredients remain unspecified in the announcement. This development follows a trend of expanding pharmaceutical roles for pharmacies in Germany, including recent authorization to administer certain vaccines and dispense select prescription medicines without a doctor’s direct involvement.
Timeline
- — Zügelt den Appetit: Abnehmtablette kommt in deutsche Apotheken - Ein Überblick (Handelsblatt)
- — Gesundheitsreform: Impfen ohne Arzt – Mehr Kompetenzen für Apotheken verärgern die Ärzteschaft (Handelsblatt)
- — Versorgung: Mehr Freiraum bei Öffnungszeiten für Apotheken (Handelsblatt)
Analysis — what this means
Likely next events
- Launch of oral weight-loss tablets in German pharmacies expected autumn 2026
- Potential reimbursement decisions by German statutory health insurers (GKV) by Q1 2027
- Possible inclusion in national diabetes and obesity treatment guidelines by mid-2027
Sectors affected
- Pharmaceutical retail
- Anti-obesity drug manufacturers
- German statutory health insurance (GKV)
Regulatory implications
- AMK price negotiations under AMNOG process if classified as prescription-only
- Pharmacy dispensing rights reinforced under recent healthcare reforms
- Pharmacovigilance reporting requirements for outpatient oral GLP-1 use
Historical parallels
- Introduction of orlistat (Xenical) as first oral anti-obesity drug in EU, early 2000s
- Expansion of pharmacy-administered vaccinations in Germany, 2022–2023
- Launch of semaglutide (Wegovy) in Germany, 2022
Key entities
Sources
Open the full interactive case file on Beyond →